Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

BioAegis publishes data on protein’s role in regulating immune cell inflammatory response 

By Brian Buntz | September 28, 2021

BioAegisPrivately-held BioAegis Therapeutics has announced that researchers have identified a previously unknown role of the protein gelsolin in regulating immune responses.

BioAegis’s therapeutic focus is to restore waning gelsolin levels associated with disease.

In a paper published in The Journal of Immunology, researchers reported that the gelsolin is involved in a signaling system in macrophages, which are a type of white blood cell. In particular, the paper found that macrophages exhibit quorum sensing, which involves regulating gene expression based on changes in cell-population density. While scientists have long known about bacterial quorum sensing, they were previously unaware of its role in regulating immune cell inflammatory responses.

The North Brunswick, New Jersey–based company reported that it is inspired by the therapeutic implications of the findings. “There are many layers to the science underlying gelsolin’s role as a master regulator in immunity,” said Dr. Susan Levinson, CEO of BioAegis, in a statement. “The more we learn about this key signaling protein, the more we look forward to bringing rhu-pGSN to patients.”

Gelsolin is a naturally occurring human protein.

BioAegis said that the findings from the Journal of Immunology study are consistent with the anti-inflammatory properties the company has observed relative to its recombinant human plasma gelsolin (rhu-pGSN) treatment.

The company has studied the investigational drug in a variety of animal models focused on inflammatory disease.

BioAegis is also evaluating data from a Phase 2 study related to gelsolin as an adjunct to standard of care in patients with severe COVID-19 pneumonia.

The company has also published a compassionate use case study using gelsolin in a hospitalized patient with critical COVID-19 pneumonia.

In June, the company announced that it won a BARDA contract to support the development of gelsolin for sepsis and severe infection.


Filed Under: Drug Discovery, Immunology, Infectious Disease
Tagged With: BioAegis, gelsolin, immunity, macrophages, quorum sensing, rhu-pGSN
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio
Axcella
Axcella touts positive results from Phase 2a long COVID study
artificial intelligence
Defining complexity: A framework to identify complex clinical trials and set them up for success

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50